Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.62 |
| ▸ | MET | P08581 | 13/20 | 0.61 |
| ▸ | AXL | P30530 | 4/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22407477 | 0.87 | PDGFRA (0.54) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL22407579 | 0.87 | MET (0.53) | FGFR2PDGFRAMETKDR | |
| SCHEMBL5049533 | 0.86 | FGFR2 (0.71) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL29822421 | 0.85 | FGFR2 (0.67) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL2573722 | 0.85 | FGFR2 (0.67) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL23617110 | 0.85 | FGFR2 (0.67) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL22407393 | 0.84 | PDGFRA (0.54) | FGFR2PDGFRAMETAXLKDR | |
| SCHEMBL22407317 | 0.84 | PDGFRA (0.59) | FGFR2PDGFRAMETKDR | |
| SCHEMBL22407555 | 0.83 | FGFR2 (0.71) | FGFR2PDGFRAAXLKDR | |
| SCHEMBL5056203 | 0.83 | PDGFRA (0.72) | FGFR2PDGFRAMETAXLKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | FGFR2 4496/4885PDGFRA 624/4885MET 3803/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | FGFR2 4496/4885PDGFRA 624/4885MET 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.